No matches
Pulmonology

Exploring the Mechanisms of FeNO Production in the Lungs

Explore how type 2 inflammation drives the production of FeNO in severe asthma

Related resources

Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

videoanimation
How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

videoanimation
EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

videoanimation
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

Podcast
What Do We Know About Type 2 Inflammation in COPD?

What Do We Know About Type 2 Inflammation in COPD?

expert video
What Differentiates COPD Exacerbations From Asthma Exacerbations?

What Differentiates COPD Exacerbations From Asthma Exacerbations?

expert video
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

expert video
ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

expert video
What Is The COPD Vicious Cycle?

What Is The COPD Vicious Cycle?

expert video
Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

videoanimation
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

interactivity
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden

ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden

Podcast
ADVENT On Air | Role of Type 2 Inflammation in COPD

ADVENT On Air | Role of Type 2 Inflammation in COPD

Podcast
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

Podcast
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

expert video
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video
GOLD Diagnosis and Assessment of COPD

GOLD Diagnosis and Assessment of COPD

expert video
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Eosinophils: A Biomarker in COPD

Eosinophils: A Biomarker in COPD

Infographic
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video

Learning objectives

  • Identify FeNO as a marker of type 2 inflammation in severe asthma patients

Description

Fractional exhaled nitric oxide (FeNO), one of the three biomarkers of type 2 inflammation in asthma, is produced as a result of type 2 inflammation. Explore this process and the role of FeNO in healthy individuals and patients with asthma.

Tags
biomarkerstype 2 inflammationfeno
MAT-GLB-2507149 - 1.0 - 03/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region